Use of acid-suppressive drugs and risk of fracture: A meta-analysis of observational studies

Annals of Family Medicine

Volumn 9, Issue 3, 2011, Pages 257-267

  Eom, Chun Sick ^a   Park, Sang Min ^a   Myung, Seung Kwon ^a,b   Yun, Jae Moon ^a   Ahn, Jeong Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Fracture risk; Meta analysis; Proton pump inhibitors

Indexed keywords

ANTIULCER AGENT; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ARTICLE; CHEMICALLY INDUCED DISORDER; CONFIDENCE INTERVAL; FRACTURE; GASTROESOPHAGEAL REFLUX; HUMAN; META ANALYSIS; METHODOLOGY; RISK; RISK ASSESSMENT; RISK FACTOR; SECRETION; STOMACH ACID;

ANTI-ULCER AGENTS; CIMETIDINE; CONFIDENCE INTERVALS; FRACTURES, BONE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; ODDS RATIO; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS;

EID: 79957583113     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1243     Document Type: Review

References (65)

1. CAG Clinical Affairs Committee. Community-acquired pneumonia and acid-suppressive drugs: position statement. Can J Gastroenterol. 2006;20(2):119-121, 123-125.
2. Eastell R, Lambert H. Strategies for skeletal health in the elderly. Proc Nutr Soc. 2002;61(2):173-180.
3. Seeman E, Bianchi G, Adami S, Kanis J, Khosla S, Orwoll E. Osteoporosis in men-consensus is premature. Calcif Tissue Int. 2004; 75(2):120-122.
4. Roughead EE, Ramsay EN, Pratt NL, Ryan P, Gilbert AL. Protonpump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust. 2009;190(3):114-116.
5. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98(1):51-58.
6. Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine. J Gastroenterol Hepatol. 2007;22(5): 639-644.
7. Tuukkanen J, Väänänen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123-125.
8. Zaidi M. Modularity of osteoclast behaviour and "mode-specific" inhibition of osteoclast function. Biosci Rep. 1990;10(6):547-556.
9. Sahara T, Itoh K, Debari K, Sasaki T. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts. Anat Rec A Discov Mol Cell Evol Biol. 2003;270(2):152-161.
10. Sasaki T. Recent advances in the ultrastructural assessment of osteoclastic resorptive functions. Microsc Res Tech. 1996;33(2):182-191.
11. Shibata T, Amano H, Yamada S, Ohya K. Mechanisms of proton transport in isolated rat osteoclasts attached to bone. J Med Dent Sci. 2000;47(3):177-185.
12. Gagliardi S, Nadler G, Consolandi E, et al. 5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity. J Med Chem. 1998;41(10):1568-1573.
13. Rzeszutek K, Sarraf F, Davies JE. Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac Surg. 2003;14(3):301-307.
14. Sundquist K, Lakkakorpi P, Wallmark B, Väänänen K. Inhibition of osteoclast proton transport by bafilomycin A1 abolishes bone resorption. Biochem Biophys Res Commun. 1990;168(1):309-313.
15. Visentin L, Dodds RA, Valente M, et al. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest. 2000;106(2):309-318.
16. Xu J, Feng HT, Wang C, et al. Effects of bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts. J Cell Biochem. 2003;88(6):1256-1264.
17. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21-25.
18. Shangraw RF. Factors to consider in the selection of a calcium supplement. Public Health Rep. 1989;104(Suppl):46-50.
19. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73(3): 640-647.
20. Nordin BE. Calcium and osteoporosis. Nutrition. 1997;13(7-8): 664-686.
21. Wood RJ, Serfaty-Lacrosniere C. Gastric acidity, atrophic gastritis, and calcium absorption. Nutr Rev. 1992;50(2):33-40.
22. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953.
23. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326.
24. Zhang Y, Lai WP, Wu CF, Favus MJ, Leung PC, Wong MS. Ovariectomy worsens secondary hyperparathyroidism in mature rats during low-Ca diet. Am J Physiol Endocrinol Metab. 2007;292(3):E723-E731.
25. Ueyama T, Shirasawa N, Ito T, Tsuruo Y. Estrogen-producing steroidogenic pathways in parietal cells of the rat gastric mucosa. Life Sci. 2004;74(18):2327-2337.
26. Ueyama T, Shirasawa N, Numazawa M, et al. Gastric parietal cells: potent endocrine role in secreting estrogen as a possible regulator of gastro-hepatic axis. Endocrinology. 2002;143(8):3162-3170.
27. Campbell-Thompson M, Reyher KK, Wilkinson LB. Immunolocalization of estrogen receptor alpha and beta in gastric epithelium and enteric neurons. J Endocrinol. 2001;171(1):65-73.
28. Sozzi M, Valentini M, Figura N, et al. Atrophic gastritis and intestinal metaplasia in Helicobacter pylori infection: the role of CagA status. Am J Gastroenterol. 1998;93(3):375-379.
29. Sakata I, Tanaka T, Yamazaki M, Tanizaki T, Zheng Z, Sakai T. Gastric estrogen directly induces ghrelin expression and production in the rat stomach. J Endocrinol. 2006;190(3):749-757.
30. Matsubara M, Sakata I, Wada R, Yamazaki M, Inoue K, Sakai T. Estrogen modulates ghrelin expression in the female rat stomach. Peptides. 2004;25(2):289-297.
31. Fukushima N, Hanada R, Teranishi H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res. 2005;20(5):790-798.
32. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008;179(4):306-307.
33. Schuler A. Risks versus benefits of long-term proton pump inhibitor therapy in the elderly. Geriatr Nurs. 2007;28(4):225-229.
34. Landahl S, Andersson T, Larsson M, et al. Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet. 1992;23(6):469-476.
35. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89(8 Suppl):S116-S128.
36. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med. 1967;66(5):917-923.
37. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70-73.
38. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1995;9(Suppl 1):9-14.
39. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76-83.
40. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251-259.
41. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84(1):13-19.
42. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959.
43. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
44. Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003;139(6):476-482.
45. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993-1000.
46. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in metaanalyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed December 12, 2010.
47. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21(11):1539-1558.
48. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
49. Grisso JA, Kelsey JL, O'Brien LA, et al; Hip Fracture Study Group. Risk factors for hip fracture in men. Am J Epidemiol. 1997;145(9): 786-793.
50. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93-101.
51. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170(9):765-771.
52. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based casecontrol study. Osteoporos Int. 2011;22(3):903-910.
53. Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11): 1131-1136.
54. Olbe L, Cederberg C, Lind T, Olausson M. Effect of omeprazole on gastric acid secretion and plasma gastrin in man. Scand J Gastroenterol Suppl. 1989;166:27-32, discussion 41-42.
55. Lesclous P, Guez D, Baroukh B, Vignery A, Saffar JL. Histamine participates in the early phase of trabecular bone loss in ovariectomized rats. Bone. 2004;34(1):91-99.
56. Lesclous P, Guez D, Saffar JL. Short-term prevention of osteoclastic resorption and osteopenia in ovariectomized rats treated with the H(2) receptor antagonist cimetidine. Bone. 2002;30(1):131-136.
57. Yamaura K, Yonekawa T, Nakamura T, Yano S, Ueno K. The histamine H2-receptor antagonist, cimetidine, inhibits the articular osteopenia in rats with adjuvant-induced arthritis by suppressing the osteoclast differentiation induced by histamine. J Pharmacol Sci. 2003;92(1):43-49.
58. Dobigny C, Saffar JL. H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol. 1997;173(1):10-18.
59. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int. 1998;62(4):283-285.
60. Mattsson JP, Väänänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta. 1991;1065(2):261-268.
61. Bodmer M, Meier C, Kraenzlin ME, Meier CR. Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf. 2010;33(10):843-852.
62. Figura N, Gennari L, Merlotti D, et al. Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. Dig Dis Sci. 2005;50(5):847-852.
63. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407-413.
64. Kanis JA. The incidence of hip fracture in Europe. Osteoporos Int. 1993;3(Suppl 1):10-15.
65. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7): 778-781.